O	0	11	Bradycardia	Bradycardia	NNP	B-NP
O	11	12	-	-	HYPH	B-NP
O	12	19	induced	induce	VBN	I-NP
B-Multi-tissue_structure	20	28	coronary	coronary	JJ	I-NP
O	29	41	angiogenesis	angiogenesis	NN	I-NP
O	42	44	is	be	VBZ	B-VP
O	45	54	dependent	dependent	JJ	B-ADJP
O	55	57	on	on	IN	B-PP
O	58	66	vascular	vascular	JJ	B-NP
O	67	78	endothelial	endothelial	JJ	I-NP
O	79	85	growth	growth	NN	I-NP
O	86	92	factor	factor	NN	I-NP
O	92	93	.	.	.	O

O	94	95	A	A	DT	B-NP
O	96	102	marked	marked	JJ	I-NP
B-Multi-tissue_structure	103	111	coronary	coronary	JJ	I-NP
O	112	124	angiogenesis	angiogenesis	NN	I-NP
O	125	127	is	be	VBZ	B-VP
O	128	133	known	know	VBN	I-VP
O	134	136	to	to	TO	I-VP
O	137	142	occur	occur	VB	I-VP
O	143	147	with	with	IN	B-PP
O	148	155	chronic	chronic	JJ	B-NP
O	156	167	bradycardia	bradycardia	NN	I-NP
O	167	168	.	.	.	O

O	169	171	We	We	PRP	B-NP
O	172	178	tested	test	VBD	B-VP
O	179	182	the	the	DT	B-NP
O	183	193	hypothesis	hypothesis	NN	I-NP
O	194	198	that	that	IN	B-SBAR
O	199	207	vascular	vascular	JJ	B-NP
O	208	219	endothelial	endothelial	JJ	I-NP
O	220	226	growth	growth	NN	I-NP
O	227	233	factor	factor	NN	I-NP
O	234	235	(	(	(	O
O	235	239	VEGF	VEGF	NN	B-NP
O	239	240	)	)	)	O
O	240	241	,	,	,	O
O	242	244	an	an	DT	B-NP
B-Cell	245	256	endothelial	endothelial	JJ	I-NP
I-Cell	257	261	cell	cell	NN	I-NP
O	262	269	mitogen	mitogen	NN	I-NP
O	270	273	and	and	CC	O
O	274	275	a	a	DT	B-NP
O	276	281	major	major	JJ	I-NP
O	282	291	regulator	regulator	NN	I-NP
O	292	294	of	of	IN	B-PP
O	295	307	angiogenesis	angiogenesis	NN	B-NP
O	307	308	,	,	,	O
O	309	311	is	be	VBZ	B-VP
O	312	323	upregulated	upregulate	VBN	I-VP
O	324	326	in	in	IN	B-PP
O	327	335	response	response	NN	B-NP
O	336	338	to	to	TO	B-PP
O	339	342	low	low	JJ	B-NP
B-Organ	343	348	heart	heart	NN	I-NP
O	349	353	rate	rate	NN	I-NP
O	354	357	and	and	CC	O
O	358	371	consequential	consequential	JJ	B-NP
O	372	381	increased	increase	VBN	I-NP
O	382	388	stroke	stroke	NN	I-NP
O	389	395	volume	volume	NN	I-NP
O	395	396	.	.	.	O

O	397	408	Bradycardia	Bradycardia	NNP	B-NP
O	409	412	was	be	VBD	B-VP
O	413	420	induced	induce	VBN	I-VP
O	421	423	in	in	IN	B-PP
O	424	428	rats	rat	NNS	B-NP
O	429	431	by	by	IN	B-PP
O	432	445	administering	administer	VBG	B-VP
O	446	449	the	the	DT	B-NP
O	450	461	bradycardic	bradycardic	JJ	I-NP
O	462	466	drug	drug	NN	I-NP
O	467	476	alinidine	alinidine	NN	I-NP
O	477	478	(	(	(	O
O	478	479	3	3	CD	B-NP
O	480	482	mg	mg	NN	I-NP
O	482	483	/	/	SYM	B-NP
O	483	485	kg	kg	NN	I-NP
B-Organism_subdivision	486	490	body	body	NN	I-NP
O	491	497	weight	weight	NN	I-NP
O	497	498	)	)	)	O
O	499	504	twice	twice	RB	B-ADVP
O	505	510	daily	daily	RB	I-ADVP
O	510	511	.	.	.	O

B-Organ	512	517	Heart	Heart	NN	B-NP
O	518	522	rate	rate	NN	I-NP
O	523	532	decreased	decrease	VBD	B-VP
O	533	535	by	by	IN	B-PP
O	536	538	32	32	CD	B-NP
O	538	539	%	%	NN	I-NP
O	540	543	for	for	IN	B-PP
O	544	546	20	20	CD	B-NP
O	547	549	to	to	TO	I-NP
O	550	552	40	40	CD	I-NP
O	553	560	minutes	minute	NNS	I-NP
O	561	566	after	after	IN	B-PP
O	567	576	injection	injection	NN	B-NP
O	577	580	and	and	CC	O
O	581	584	was	be	VBD	B-VP
O	585	596	chronically	chronically	RB	I-VP
O	597	604	reduced	reduce	VBN	I-VP
O	605	607	by	by	IN	B-PP
O	608	610	10	10	CD	B-NP
O	610	611	%	%	NN	I-NP
O	611	612	,	,	,	O
O	613	615	14	14	CD	B-NP
O	615	616	%	%	NN	I-NP
O	616	617	,	,	,	O
O	618	621	and	and	CC	O
O	622	624	18	18	CD	B-NP
O	624	625	.	.	.	O
O	625	626	5	5	CD	B-NP
O	626	627	%	%	NN	I-NP
O	628	633	after	after	IN	B-PP
O	634	635	1	1	CD	B-NP
O	635	636	,	,	,	I-NP
O	637	638	2	2	CD	I-NP
O	638	639	,	,	,	O
O	640	643	and	and	CC	O
O	644	645	3	3	CD	B-NP
O	646	651	weeks	week	NNS	I-NP
O	652	654	of	of	IN	B-PP
O	655	664	treatment	treatment	NN	B-NP
O	664	665	,	,	,	O
O	666	678	respectively	respectively	RB	B-ADVP
O	678	679	.	.	.	O

B-Multi-tissue_structure	680	688	Arterial	Arterial	JJ	B-NP
O	689	697	pressure	pressure	NN	I-NP
O	698	701	and	and	CC	O
B-Organ	702	709	cardiac	cardiac	JJ	B-NP
O	710	716	output	output	NN	I-NP
O	717	721	were	be	VBD	B-VP
O	722	731	unchanged	unchanged	JJ	B-ADJP
O	731	732	.	.	.	O

B-Tissue	733	737	Left	Leave	VBN	B-NP
I-Tissue	738	749	ventricular	ventricular	JJ	I-NP
I-Tissue	750	759	capillary	capillary	JJ	I-NP
O	760	766	length	length	NN	I-NP
O	767	774	density	density	NN	I-NP
O	775	776	(	(	(	O
O	776	778	mm	mm	NN	B-NP
O	778	779	/	/	SYM	O
O	779	781	mm	mm	NN	B-NP
O	781	782	(	(	(	O
O	782	783	3	3	CD	B-NP
O	783	784	)	)	)	O
O	784	785	)	)	)	O
O	786	795	increased	increase	VBD	B-VP
O	796	805	gradually	gradually	RB	B-ADVP
O	806	810	with	with	IN	B-PP
O	811	820	alinidine	alinidine	NN	B-NP
O	821	835	administration	administration	NN	I-NP
O	835	836	;	;	:	O
O	837	838	a	a	DT	B-NP
O	839	841	15	15	CD	I-NP
O	841	842	%	%	NN	I-NP
O	843	851	increase	increase	NN	I-NP
O	852	857	after	after	IN	B-PP
O	858	859	2	2	CD	B-NP
O	860	865	weeks	week	NNS	I-NP
O	866	869	and	and	CC	O
O	870	871	a	a	DT	B-NP
O	872	874	40	40	CD	I-NP
O	874	875	%	%	NN	I-NP
O	876	884	increase	increase	NN	I-NP
O	885	890	after	after	IN	B-PP
O	891	892	3	3	CD	B-NP
O	893	898	weeks	week	NNS	I-NP
O	899	901	of	of	IN	B-PP
O	902	911	alinidine	alinidine	NN	B-NP
O	912	921	treatment	treatment	NN	I-NP
O	922	926	were	be	VBD	B-VP
O	927	937	documented	document	VBN	I-VP
O	937	938	.	.	.	O

B-Multi-tissue_structure	939	943	Left	Leave	VBN	B-NP
I-Multi-tissue_structure	944	955	ventricular	ventricular	JJ	I-NP
O	956	962	weight	weight	NN	I-NP
O	962	963	,	,	,	O
B-Organism_subdivision	964	968	body	body	NN	B-NP
O	969	975	weight	weight	NN	I-NP
O	975	976	,	,	,	O
O	977	980	and	and	CC	O
O	981	986	their	their	PRP$	B-NP
O	987	992	ratio	ratio	NN	I-NP
O	993	997	were	be	VBD	B-VP
O	998	1001	not	not	RB	I-VP
O	1002	1015	significantly	significantly	RB	I-VP
O	1016	1023	altered	alter	VBN	I-VP
O	1024	1026	by	by	IN	B-PP
O	1027	1036	alinidine	alinidine	NN	B-NP
O	1037	1046	treatment	treatment	NN	I-NP
O	1046	1047	.	.	.	O

O	1048	1053	After	After	IN	B-PP
O	1054	1055	1	1	CD	B-NP
O	1056	1060	week	week	NN	I-NP
O	1061	1063	of	of	IN	B-PP
O	1064	1073	treatment	treatment	NN	B-NP
O	1073	1074	,	,	,	O
O	1075	1081	before	before	IN	B-PP
O	1082	1084	an	an	DT	B-NP
O	1085	1093	increase	increase	NN	I-NP
O	1094	1096	in	in	IN	B-PP
B-Tissue	1097	1106	capillary	capillary	JJ	B-NP
O	1107	1113	length	length	NN	I-NP
O	1114	1121	density	density	NN	I-NP
O	1121	1122	,	,	,	O
O	1123	1127	VEGF	VEGF	NN	B-NP
O	1128	1132	mRNA	mRNA	NN	I-NP
O	1133	1142	increased	increase	VBD	B-VP
O	1144	1151	greater	great	JJR	B-NP
O	1152	1156	than	than	IN	I-NP
O	1157	1158	2	2	CD	I-NP
O	1158	1159	-	-	HYPH	I-NP
O	1159	1163	fold	fold	RB	I-NP
O	1164	1167	and	and	CC	O
O	1168	1172	then	then	RB	O
O	1173	1181	declined	decline	VBD	B-VP
O	1182	1184	to	to	TO	B-PP
O	1185	1192	control	control	NN	B-NP
O	1193	1199	levels	level	NNS	I-NP
O	1200	1205	after	after	IN	B-PP
O	1206	1207	3	3	CD	B-NP
O	1208	1213	weeks	week	NNS	I-NP
O	1214	1216	of	of	IN	B-PP
O	1217	1226	treatment	treatment	NN	B-NP
O	1226	1227	.	.	.	O

O	1228	1232	VEGF	VEGF	NN	B-NP
O	1233	1240	protein	protein	NN	I-NP
O	1241	1244	was	be	VBD	B-VP
O	1245	1251	higher	high	JJR	B-ADJP
O	1252	1254	in	in	IN	B-PP
O	1255	1264	alinidine	alinidine	NN	B-NP
O	1264	1265	-	-	HYPH	B-NP
O	1265	1272	treated	treat	VBN	I-NP
O	1273	1277	rats	rat	NNS	I-NP
O	1278	1282	than	than	IN	B-PP
O	1283	1285	in	in	IN	B-PP
O	1286	1294	controls	control	NNS	B-NP
O	1295	1300	after	after	IN	B-PP
O	1301	1302	2	2	CD	B-NP
O	1303	1308	weeks	week	NNS	I-NP
O	1309	1312	and	and	CC	O
O	1313	1322	increased	increase	VBN	B-VP
O	1323	1330	further	further	RB	B-ADVP
O	1331	1336	after	after	IN	B-PP
O	1337	1338	3	3	CD	B-NP
O	1339	1344	weeks	week	NNS	I-NP
O	1345	1347	of	of	IN	B-PP
O	1348	1357	treatment	treatment	NN	B-NP
O	1357	1358	.	.	.	O

O	1359	1368	Injection	Injection	NN	B-NP
O	1369	1371	of	of	IN	B-PP
O	1372	1376	VEGF	VEGF	NN	B-NP
O	1376	1377	-	-	HYPH	O
O	1377	1389	neutralizing	neutralize	VBG	B-VP
O	1390	1400	antibodies	antibody	NNS	B-NP
O	1401	1405	over	over	IN	B-PP
O	1406	1407	a	a	DT	B-NP
O	1408	1409	2	2	CD	I-NP
O	1409	1410	-	-	HYPH	I-NP
O	1410	1414	week	week	NN	I-NP
O	1415	1421	period	period	NN	I-NP
O	1422	1432	completely	completely	RB	B-ADVP
O	1433	1440	blocked	block	VBD	B-VP
O	1441	1450	alinidine	alinidine	NN	B-NP
O	1450	1451	-	-	HYPH	O
O	1451	1461	stimulated	stimulate	VBN	B-NP
O	1462	1474	angiogenesis	angiogenesis	NN	I-NP
O	1474	1475	.	.	.	O

O	1476	1478	In	In	IN	B-PP
O	1479	1487	contrast	contrast	NN	B-NP
O	1487	1488	,	,	,	O
O	1489	1493	bFGF	bFGF	NN	B-NP
O	1494	1498	mRNA	mRNA	NN	I-NP
O	1499	1502	was	be	VBD	B-VP
O	1503	1506	not	not	RB	I-VP
O	1507	1514	altered	alter	VBN	I-VP
O	1515	1517	by	by	IN	B-PP
O	1518	1527	alinidine	alinidine	NN	B-NP
O	1528	1537	treatment	treatment	NN	I-NP
O	1537	1538	.	.	.	O

O	1539	1544	These	These	DT	B-NP
O	1545	1549	data	datum	NNS	I-NP
O	1550	1557	suggest	suggest	VBP	B-VP
O	1558	1562	that	that	IN	B-SBAR
O	1563	1567	VEGF	VEGF	NN	B-NP
O	1568	1573	plays	play	VBZ	B-VP
O	1574	1575	a	a	DT	B-NP
O	1576	1579	key	key	JJ	I-NP
O	1580	1584	role	role	NN	I-NP
O	1585	1587	in	in	IN	B-PP
O	1588	1591	the	the	DT	B-NP
O	1592	1602	angiogenic	angiogenic	JJ	I-NP
O	1603	1611	response	response	NN	I-NP
O	1612	1616	that	that	WDT	B-NP
O	1617	1623	occurs	occur	VBZ	B-VP
O	1624	1628	with	with	IN	B-PP
O	1629	1636	chronic	chronic	JJ	B-NP
O	1637	1648	bradycardia	bradycardia	NN	I-NP
O	1648	1649	.	.	.	O

O	1650	1653	The	The	DT	B-NP
O	1654	1663	mechanism	mechanism	NN	I-NP
O	1664	1674	underlying	underlie	VBG	B-VP
O	1675	1679	this	this	DT	B-NP
O	1680	1684	VEGF	VEGF	NN	I-NP
O	1684	1685	-	-	HYPH	B-VP
O	1685	1695	associated	associate	VBN	B-NP
O	1696	1708	angiogenesis	angiogenesis	NN	I-NP
O	1709	1712	may	may	MD	B-VP
O	1713	1715	be	be	VB	I-VP
O	1716	1718	an	an	DT	B-NP
O	1719	1727	increase	increase	NN	I-NP
O	1728	1730	in	in	IN	B-PP
O	1731	1738	stretch	stretch	NN	B-NP
O	1739	1742	due	due	JJ	B-PP
O	1743	1745	to	to	TO	B-PP
O	1746	1754	enhanced	enhance	VBN	B-NP
O	1755	1764	diastolic	diastolic	JJ	I-NP
O	1765	1772	filling	filling	NN	I-NP
O	1772	1773	.	.	.	O

